Insider Purchase
On June 26, 2026, Eliyahou Harari, who owns approximately ten percent of CapsoVision Inc. (CV), acquired 13,850 shares of the company’s common stock for a total consideration of $101,811. The transaction price was $7.351 per share.
Shareholding Impact
Following this acquisition, Harari’s indirect ownership in CapsoVision increased to 3,200,751 shares. These shares are held in the Harari Family Trust, for which Mr. Harari and his wife act as trustees.
Stock Performance
At the time of reporting, CapsoVision’s shares were trading at $5.67, representing a decline of roughly 23% from the purchase price of $7.351. The stock had fallen more than 23% over the preceding week, and InvestingPro’s analysis labeled the security as overvalued relative to its fair‑value, placing it on a “Most Overvalued” list.
Recent Financial Results
CapsoVision released its first‑quarter 2026 earnings, posting earnings per share of –$0.15, compared with consensus expectations of –$0.11. This constituted a 36.36% negative earnings surprise.
Analyst Rating
Benchmark reiterated a Speculative Buy rating on CapsoVision stock and set a price target of $10 per share. The firm noted that the company’s product development programs remain on schedule, with regulatory submissions and clinical trials anticipated in the near term.
Corporate Governance Updates
During its annual meeting, shareholders re‑elected three Class I directors and approved the appointment of an independent auditor. Additionally, CapsoVision appointed Dr. David S. Shields, a gastroenterologist, to its Board of Directors.
This article was generated with AI assistance and reviewed by an editor.